Similar articles

• Neuraminidase and concanavalin A in the experimental immunotherapy of cancer.

  Simmons RL, Rios A. Simmons RL, et al. Johns Hopkins Med J Suppl. 1974;3:75-84. Johns Hopkins Med J Suppl. 1974. PMID: 4536589 No abstract available.
• Neuraminidase treated cells and their role in cancer immunotherapy.

  Simmons RL, Rios A. Simmons RL, et al. Birth Defects Orig Artic Ser. 1973 Mar;9(2):223-8. Birth Defects Orig Artic Ser. 1973. PMID: 4611534 Review. No abstract available.
• Cell surface modification in the treatment of experimental cancer: neuraminidase or concanavalin A.

  Simmons RL, Rios A. Simmons RL, et al. Cancer. 1974 Oct;34(4 Suppl):suppl:1541-7. doi: 10.1002/1097-0142(197410)34:8+<1541::aid-cncr2820340828>3.0.co;2-g. Cancer. 1974. PMID: 4138077 No abstract available.
• Active specific immunotherapy of minimal residual tumor: excision plus neuraminidase-treated tumor cells.

  Rios A, Simmons RL. Rios A, et al. Int J Cancer. 1974 Jan 15;13(1):71-81. doi: 10.1002/ijc.2910130109. Int J Cancer. 1974. PMID: 4818273 No abstract available.
• Aspects of microbiology in cancer research.

  Rosenkranz HS. Rosenkranz HS. Annu Rev Microbiol. 1973;27:383-401. doi: 10.1146/annurev.mi.27.100173.002123. Annu Rev Microbiol. 1973. PMID: 4584691 Review. No abstract available.